Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:AVTX NASDAQ:CRMD NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.41+3.2%$7.23$4.73▼$9.53$642.03M0.39467,401 shs959,149 shsAVTXAvalo Therapeutics$14.76+8.0%$15.68$4.46▼$24.27$718.57M0.831.39 million shs1.12 million shsCRMDCorMedix$8.74-2.5%$7.81$6.13▼$17.43$702.93M1.461.30 million shs968,765 shsRNACCartesian Therapeutics$9.51+18.0%$6.95$5.60▼$15.57$236.82M0.66366,818 shs877,601 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+1.47%-8.68%-21.69%+4.55%-6.33%AVTXAvalo Therapeutics+4.35%+0.44%-31.44%-13.48%+190.23%CRMDCorMedix+2.17%+4.92%+19.31%+38.91%-38.59%RNACCartesian Therapeutics+8.48%+23.05%-7.36%+9.07%-22.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.41+3.2%$7.23$4.73▼$9.53$642.03M0.39467,401 shs959,149 shsAVTXAvalo Therapeutics$14.76+8.0%$15.68$4.46▼$24.27$718.57M0.831.39 million shs1.12 million shsCRMDCorMedix$8.74-2.5%$7.81$6.13▼$17.43$702.93M1.461.30 million shs968,765 shsRNACCartesian Therapeutics$9.51+18.0%$6.95$5.60▼$15.57$236.82M0.66366,818 shs877,601 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+1.47%-8.68%-21.69%+4.55%-6.33%AVTXAvalo Therapeutics+4.35%+0.44%-31.44%-13.48%+190.23%CRMDCorMedix+2.17%+4.92%+19.31%+38.91%-38.59%RNACCartesian Therapeutics+8.48%+23.05%-7.36%+9.07%-22.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50219.81% UpsideAVTXAvalo Therapeutics 2.85Moderate Buy$46.67216.17% UpsideCRMDCorMedix 2.75Moderate Buy$15.0071.62% UpsideRNACCartesian Therapeutics 2.67Moderate Buy$32.60242.80% UpsideCurrent Analyst Ratings BreakdownLatest RNAC, CRMD, AURA, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026AVTXAvalo Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.006/10/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.006/9/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/9/2026RNACCartesian Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/27/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.005/26/2026AVTXAvalo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$42.00 ➝ $40.005/15/2026CRMDCorMedix Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026CRMDCorMedix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/14/2026AVTXAvalo Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$62.00 ➝ $55.005/14/2026AVTXAvalo Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$40.00 ➝ $34.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/AAVTXAvalo Therapeutics$60K12,932.22N/AN/A$4.49 per share3.29CRMDCorMedix$311.71M2.20$2.00 per share4.38$5.14 per share1.70RNACCartesian Therapeutics$2.80M99.79N/AN/A($4.85) per share-1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)AVTXAvalo Therapeutics-$78.26M-$5.46N/AN/AN/AN/A-97.54%-72.42%8/6/2026 (Estimated)CRMDCorMedix$163.05M$2.134.1048.56N/A45.25%45.57%24.76%8/6/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)Latest RNAC, CRMD, AURA, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/14/2026Q1 2026CRMDCorMedix$0.35$0.43+$0.08$0.43$104.96 million$127.43 million5/13/2026Q1 2026AVTXAvalo Therapeutics-$1.00-$0.98+$0.02-$0.98$0.05 millionN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 million3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/23/2026Q4 2025AVTXAvalo Therapeutics-$1.54-$0.37+$1.17-$0.37($0.21) million$0.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09AVTXAvalo TherapeuticsN/A7.667.66CRMDCorMedix0.332.972.74RNACCartesian TherapeuticsN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%AVTXAvalo Therapeutics87.06%CRMDCorMedix34.18%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%AVTXAvalo Therapeutics4.46%CRMDCorMedix3.50%RNACCartesian Therapeutics37.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million96.87 millionNot OptionableAVTXAvalo Therapeutics4052.57 million50.22 millionNot OptionableCRMDCorMedix3078.45 million75.71 millionOptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableRNAC, CRMD, AURA, and AVTX HeadlinesRecent News About These CompaniesCartesian Therapeutics Announces New Employment Inducement GrantJune 12 at 4:05 PM | globenewswire.comWedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 12 at 9:25 AM | theglobeandmail.comCartesian climbs on licensing deal with WestGene for CAR-T therapiesJune 9 at 12:20 PM | seekingalpha.comCartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune DiseasesJune 9 at 7:00 AM | globenewswire.comCartesian Therapeutics (RNAC) Gets a Buy from WedbushMay 29, 2026 | theglobeandmail.comCartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027May 26, 2026 | globenewswire.comWe're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateMay 17, 2026 | finance.yahoo.comQ2 EPS Estimate for Cartesian Therapeutics Cut by AnalystMay 14, 2026 | marketbeat.comCartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | quiverquant.comQCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 12, 2026 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 4, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)May 2, 2026 | theglobeandmail.comCartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue EstimatesApril 30, 2026 | zacks.comCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comCartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?April 20, 2026 | zacks.comCartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 14, 2026 | seekingalpha.comCartesian Therapeutics Announces New Employment Inducement GrantsApril 2, 2026 | globenewswire.comCartesian Therapeutics (NASDAQ:RNAC) Stock, Short Interest ReportMarch 10, 2026 | benzinga.comCantor Fitzgerald upgrades Cartesian Therapeutics (RNAC)March 10, 2026 | msn.comCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateMarch 9, 2026 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 8.15%February 18, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?By Sam Quirke | May 15, 2026Slice of the Pie: Why Yum’s Deal Lifts QSRBy Jeffrey Neal Johnson | June 3, 2026Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressBy Jennifer Ryan Woods | June 11, 2026Short Sellers Are Piling Into Wingstop, But Analysts See Big UpsideBy Jennifer Ryan Woods | June 10, 2026RNAC, CRMD, AURA, and AVTX Company DescriptionsAura Biosciences NASDAQ:AURA$6.41 +0.20 (+3.22%) Closing price 04:00 PM EasternExtended Trading$6.40 -0.01 (-0.16%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Avalo Therapeutics NASDAQ:AVTX$14.76 +1.09 (+7.97%) Closing price 04:00 PM EasternExtended Trading$15.01 +0.25 (+1.69%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.CorMedix NASDAQ:CRMD$8.74 -0.22 (-2.46%) Closing price 04:00 PM EasternExtended Trading$8.86 +0.12 (+1.32%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Cartesian Therapeutics NASDAQ:RNAC$9.51 +1.45 (+17.99%) Closing price 04:00 PM EasternExtended Trading$9.58 +0.07 (+0.74%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
